Lirilumab
As of the edition of 20 October 2026, Lirilumab is an antibody: stopped in 2021; acts on KIR2DL1, KIR2DL2 and KIR2DL3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2021
- Kind
- Antibody
- Registered trials
- 13, 3 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Lungs and airways; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product3 company-target rows are on route A because of Lirilumab.
See the 3 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 9 | 4 | 2 | 3 |
| All trials | 13 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Lead sponsor of trials | 2012 to now |
| Innate Pharma | Lead sponsor of trials | 2012 to now |
| Incyte | Lead sponsor of trials | 2018 to now |